" class="no-js "lang="en-US"> AcuraBio - Medtech Alert
Friday, March 29, 2024
AcuraBio | Pharmtech Focus

AcuraBio

About AcuraBio

AcuraBio

AcuraBio Pty Ltd is one of Australia’s most experienced biopharmaceutical CDMOs, offering trusted, client-focused services to both domestic and international clients for the past 20 years. AcuraBio offers significant quality, cost, and IP assurances for biopharma companies around the world. World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research. AcuraBio has the following operating licenses: TGA (Australian FDA equivalent) license for the manufacture of human therapeutic APIs from biological and synthetic sources, APVMA (veterinary equivalent of the TGA) license for manufacture of sterile immunobiological products, OGTR license to produce products from genetically modified organisms, and a DAF facility license for import and use of biologic materials.

Related Story

Dr. Glenn Haifer and Ampersand Capital Partners Acquire Australian Biologics CDMO Luina Bio, Rebranding as AcuraBio

August 31 2022

AcuraBio (formerly Luina Bio), a leading Australian biopharmaceutical CDMO, has been acquired by biotech investor […]